PMID- 24844781
OWN - NLM
STAT- MEDLINE
DCOM- 20150218
LR  - 20171116
IS  - 1432-0584 (Electronic)
IS  - 0939-5555 (Linking)
VI  - 93
IP  - 10
DP  - 2014 Oct
TI  - High prognostic value of minimal residual disease detected by 
      flow-cytometry-enhanced fluorescence in situ hybridization in core-binding factor 
      acute myeloid leukemia (CBF-AML).
PG  - 1685-94
LID - 10.1007/s00277-014-2107-z [doi]
AB  - Acute myeloid leukemia (AML) is generally regarded as a disorder of stem cells, 
      known as leukemic initiating cells (LICs), which initiate the disease and 
      contribute to relapses. Although the phenotype of these cells remains unclear in 
      most patients, they are enriched within the CD34(+)CD38(-) population. In 
      core-binding factor (CBF) AML, the cytogenetic abnormalities also exist in LIC. 
      The aim of this study was to determine the prognostic power of minimal residual 
      disease (MRD) measured by fluorescence in situ hybridization (FISH) in 
      CD34(+)CD38(-) cells sorted by flow cytometry at different periods during 
      therapy. Thirty-six patients under 65 years of age with de novo CBF-AML treated 
      with intensive chemotherapy were retrospectively included in this study. 
      Correlations with relapse-free survival (RFS) and overall survival were evaluated 
      with univariate and multivariate analyses. FISH efficiently identified LICs in 
      the CD34(+)CD38(-) population. The presence of FISH(+)CD34(+)CD38(-) cells before 
      consolidation was negatively associated with cumulative incidence of relapse (64 
      vs 18 %, P = .012), which showed prognostic value for RFS (12 vs 68 %, P = .008) 
      and OS (11 vs 75 %, P = .0005), and retained prognostic significance for RFS in 
      multivariate analysis. The detection of FISH(+)CD34(+)CD38(-) cells before 
      consolidation therapy significantly correlated with long-term survival. 
      Fluorescence-activated cell sorting (FACS)-FISH could be potentially adopted as a 
      MRD monitor approach in clinical practice to identify CBF-AML patients at risk of 
      treatment failure during therapy.
FAU - Wang, Libing
AU  - Wang L
AD  - Department of Hematology, Institute of Hematology, Changhai Hospital, Second 
      Military Medical University, 168 Changhai Road, 200433, Shanghai, China.
FAU - Gao, Lei
AU  - Gao L
FAU - Xu, Sheng
AU  - Xu S
FAU - Gong, Shenglan
AU  - Gong S
FAU - Liu, Min
AU  - Liu M
FAU - Qiu, Huiying
AU  - Qiu H
FAU - Xu, Xiaoqian
AU  - Xu X
FAU - Ni, Xiong
AU  - Ni X
FAU - Chen, Li
AU  - Chen L
FAU - Lu, Shuqing
AU  - Lu S
FAU - Chen, Jie
AU  - Chen J
FAU - Song, Xianmin
AU  - Song X
FAU - Zhang, Weiping
AU  - Zhang W
FAU - Yang, Jianmin
AU  - Yang J
FAU - Hu, Xiaoxia
AU  - Hu X
FAU - Wang, Jianmin
AU  - Wang J
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140521
PL  - Germany
TA  - Ann Hematol
JT  - Annals of hematology
JID - 9107334
RN  - 0 (AML1-ETO fusion protein, human)
RN  - 0 (Antigens, CD34)
RN  - 0 (CBFbeta-MYH11 fusion protein)
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (Oncogene Proteins, Fusion)
RN  - 0 (RUNX1 Translocation Partner 1 Protein)
RN  - 04079A1RDZ (Cytarabine)
RN  - EC 3.2.2.6 (ADP-ribosyl Cyclase 1)
RN  - ZS7284E0ZP (Daunorubicin)
RN  - HDAC protocol
SB  - IM
MH  - ADP-ribosyl Cyclase 1
MH  - Adolescent
MH  - Adult
MH  - Antigens, CD34/analysis
MH  - Antineoplastic Combined Chemotherapy Protocols/administration & dosage
MH  - Cell Separation/methods
MH  - *Chromosome Aberrations
MH  - Consolidation Chemotherapy
MH  - Core Binding Factor Alpha 2 Subunit/genetics
MH  - Cytarabine/administration & dosage
MH  - Daunorubicin/administration & dosage
MH  - Female
MH  - Flow Cytometry/*methods
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Kaplan-Meier Estimate
MH  - Leukemia, Myeloid, Acute/drug therapy/genetics/mortality/*pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Neoplastic Stem Cells/*chemistry/pathology
MH  - Oncogene Proteins, Fusion/genetics
MH  - Prognosis
MH  - RUNX1 Translocation Partner 1 Protein
MH  - Young Adult
EDAT- 2014/05/23 06:00
MHDA- 2015/02/19 06:00
CRDT- 2014/05/22 06:00
PHST- 2014/04/04 00:00 [received]
PHST- 2014/05/08 00:00 [accepted]
PHST- 2014/05/22 06:00 [entrez]
PHST- 2014/05/23 06:00 [pubmed]
PHST- 2015/02/19 06:00 [medline]
AID - 10.1007/s00277-014-2107-z [doi]
PST - ppublish
SO  - Ann Hematol. 2014 Oct;93(10):1685-94. doi: 10.1007/s00277-014-2107-z. Epub 2014 
      May 21.